A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Toripalimab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer
Latest Information Update: 01 Jan 2026
At a glance
- Drugs Gemcitabine (Primary) ; Toripalimab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Jan 2026 New trial record